Read by QxMD icon Read

paul paik

Kyu-Tae Lee, Yuan Yao, Junwen He, Brent Fisher, Xing Sheng, Matthew Lumb, Lu Xu, Mikayla A Anderson, David Scheiman, Seungyong Han, Yongseon Kang, Abdurrahman Gumus, Rabab R Bahabry, Jung Woo Lee, Ungyu Paik, Noah D Bronstein, A Paul Alivisatos, Matthew Meitl, Scott Burroughs, Muhammad Mustafa Hussain, Jeong Chul Lee, Ralph G Nuzzo, John A Rogers
Emerging classes of concentrator photovoltaic (CPV) modules reach efficiencies that are far greater than those of even the highest performance flat-plate PV technologies, with architectures that have the potential to provide the lowest cost of energy in locations with high direct normal irradiance (DNI). A disadvantage is their inability to effectively use diffuse sunlight, thereby constraining widespread geographic deployment and limiting performance even under the most favorable DNI conditions. This study introduces a module design that integrates capabilities in flat-plate PV directly with the most sophisticated CPV technologies, for capture of both direct and diffuse sunlight, thereby achieving efficiency in PV conversion of the global solar radiation...
December 20, 2016: Proceedings of the National Academy of Sciences of the United States of America
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Christine K Zoon, Kelley M Kidwell, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: NRG Oncology/NSABP trial B-40 tested the impact of adding bevacizumab (bev) to neoadjuvant chemotherapy for operable breast cancer. Secondary endpoints included rates of surgical complications after surgery in patients who did or did not receive bev. METHODS: A total of 1206 women with HER2-negative operable breast cancer were randomly assigned to receive one of three different docetaxel-plus-anthracycline-based regimens, without or with bev (15 mg/kg every 3 weeks) for the first 6 of 8 cycles and for 10 doses postoperatively...
November 18, 2016: Annals of Surgical Oncology
Christopher D Jakubowski, Andrew J Plodkowski, Jason C Chang, Natasha Rekhtman, Afsheen Iqbal, Paul K Paik, Helena A Yu
No abstract text is available yet for this article.
October 26, 2016: Clinical Lung Cancer
Xiaobei Zhao, Xu-Qiao Chen, Eugene Han, Yue Hu, Paul Paik, Zhiyong Ding, Julia Overman, Alice L Lau, Sarah H Shahmoradian, Wah Chiu, Leslie M Thompson, Chengbiao Wu, William C Mobley
Corticostriatal atrophy is a cardinal manifestation of Huntington's disease (HD). However, the mechanism(s) by which mutant huntingtin (mHTT) protein contributes to the degeneration of the corticostriatal circuit is not well understood. We recreated the corticostriatal circuit in microfluidic chambers, pairing cortical and striatal neurons from the BACHD model of HD and its WT control. There were reduced synaptic connectivity and atrophy of striatal neurons in cultures in which BACHD cortical and striatal neurons were paired...
September 20, 2016: Proceedings of the National Academy of Sciences of the United States of America
Paul K Paik, Charles M Rudin
No abstract text is available yet for this article.
October 2016: Cancer
Paul K Paik
Mutations in EGFR stand as the archetype for somatic alterations that lead to oncogene addiction and that predict for response to targeted therapies. In this issue of Cancer Discovery, Konduri and colleagues report on a pair of novel oncogenic and actionable EGFR fusion events in a series of patients with lung adenocarcinomas, casting new light on this model gene. Cancer Discov; 6(6); 574-5. ©2016 AACRSee related article by Konduri et al., p. 601.
June 2016: Cancer Discovery
Donald M Jensen, Tarik Asselah, Douglas Dieterich, Graham R Foster, Mark S Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W Paik, David K Wong, Edward Tam, Kelly Kaita, S Victor Feinman, Jerry O Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O Böcher, Peter Ferenci
INTRODUCTION & AIM: Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection. MATERIAL AND METHODS: Patients were randomized 1:2:2 to receive placebo, faldaprevir 120 mg q.d. (12 or 24 weeks) or faldaprevir 240 mg q.d. (12 weeks) all with PegIFN/RBV (24-48 weeks)...
May 2016: Annals of Hepatology
Natasha Rekhtman, Maria C Pietanza, Matthew D Hellmann, Jarushka Naidoo, Arshi Arora, Helen Won, Darragh F Halpenny, Hangjun Wang, Shaozhou K Tian, Anya M Litvak, Paul K Paik, Alexander E Drilon, Nicholas Socci, John T Poirier, Ronglai Shen, Michael F Berger, Andre L Moreira, William D Travis, Charles M Rudin, Marc Ladanyi
PURPOSE: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a highly aggressive neoplasm, whose biologic relationship to small cell lung carcinoma (SCLC) versus non-SCLC (NSCLC) remains unclear, contributing to uncertainty regarding optimal clinical management. To clarify these relationships, we analyzed genomic alterations in LCNEC compared with other major lung carcinoma types. EXPERIMENTAL DESIGN: LCNEC (n = 45) tumor/normal pairs underwent targeted next-generation sequencing of 241 cancer genes by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) platform and comprehensive histologic, immunohistochemical, and clinical analysis...
July 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Jarushka Naidoo, Katja Schindler, Christiane Querfeld, Klaus Busam, Jane Cunningham, David B Page, Michael A Postow, Alyona Weinstein, Anna Skripnik Lucas, Kathryn T Ciccolini, Elizabeth A Quigley, Alexander M Lesokhin, Paul K Paik, Jamie E Chaft, Neil H Segal, Sandra P D'Angelo, Mark A Dickson, Jedd D Wolchok, Mario E Lacouture
Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, immune checkpoint mAbs cause cutaneous immune-related adverse events. Although the most commonly reported cutaneous toxicities are mild, a subset may persist despite therapy and can lead to severe or life-threatening toxicity. Autoimmune blistering disorders are not commonly associated with immune checkpoint mAb therapy...
2016: Cancer Immunology Research
Kelly L Bolton, Jonathan Tyrer, Honglin Song, Susan J Ramus, Maria Notaridou, Chris Jones, Tanya Sher, Aleksandra Gentry-Maharaj, Eva Wozniak, Ya-Yu Tsai, Joanne Weidhaas, Daniel Paik, David J Van Den Berg, Daniel O Stram, Celeste Leigh Pearce, Anna H Wu, Wendy Brewster, Hoda Anton-Culver, Argyrios Ziogas, Steven A Narod, Douglas A Levine, Stanley B Kaye, Robert Brown, Jim Paul, James Flanagan, Weiva Sieh, Valerie McGuire, Alice S Whittemore, Ian Campbell, Martin E Gore, Jolanta Lissowska, Hanna P Yang, Krzysztof Medrek, Jacek Gronwald, Jan Lubinski, Anna Jakubowska, Nhu D Le, Linda S Cook, Linda E Kelemen, Angela Brooks-Wilson, Leon F A G Massuger, Lambertus A Kiemeney, Katja K H Aben, Anne M van Altena, Richard Houlston, Ian Tomlinson, Rachel T Palmieri, Patricia G Moorman, Joellen Schildkraut, Edwin S Iversen, Catherine Phelan, Robert A Vierkant, Julie M Cunningham, Ellen L Goode, Brooke L Fridley, Susan Kruger-Kjaer, Jan Blaeker, Estrid Hogdall, Claus Hogdall, Jenny Gross, Beth Y Karlan, Roberta B Ness, Robert P Edwards, Kunle Odunsi, Kirsten B Moyisch, Julie A Baker, Francesmary Modugno, Tuomas Heikkinenen, Ralf Butzow, Heli Nevanlinna, Arto Leminen, Natalia Bogdanova, Natalia Antonenkova, Thilo Doerk, Peter Hillemanns, Matthias Dürst, Ingo Runnebaum, Pamela J Thompson, Michael E Carney, Marc T Goodman, Galina Lurie, Shan Wang-Gohrke, Rebecca Hein, Jenny Chang-Claude, Mary Anne Rossing, Kara L Cushing-Haugen, Jennifer Doherty, Chu Chen, Thorunn Rafnar, Soren Besenbacher, Patrick Sulem, Kari Stefansson, Michael J Birrer, Kathryn L Terry, Dena Hernandez, Daniel W Cramer, Ignace Vergote, Frederic Amant, Diether Lambrechts, Evelyn Despierre, Peter A Fasching, Matthias W Beckmann, Falk C Thiel, Arif B Ekici, Xiaoqing Chen, Sharon E Johnatty, Penelope M Webb, Jonathan Beesley, Stephen Chanock, Montserrat Garcia-Closas, Tom Sellers, Douglas F Easton, Andrew Berchuck, Georgia Chenevix-Trench, Paul D P Pharoah, Simon A Gayther
No abstract text is available yet for this article.
January 2016: Nature Genetics
Paul T Kröner, Pavan Kumar Mankal, Abdelaziz Elhaddad, Wenjing Shi, Jean Abed, Il Joon Paik, Donald Kotler
No abstract text is available yet for this article.
2015: Endoscopy
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Qing Liu, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes. As reported previously, addition of neoadjuvant bevacizumab increased the proportion of patients achieving a pathological complete response, which was the primary endpoint...
September 2015: Lancet Oncology
Guanggang Li, Hasi Wulan, Zongchang Song, Paul A Paik, Ming L Tsao, Gary M Goodman, Paul T MacEachern, Robert S Downey, Anna J Jankowska, Yaron M Rabinowitz, Thomas B Learch, David Z Song, Ji J Yuan, Shihang Zheng, Zhendong Zheng
Helicobacter pylori infection occurs in more than half of the world's population and is the main cause for gastric cancer. A series of lifestyle and nutritional factors, such as tobacco smoking and obesity, have been found to elevate the risk for cancer development. In this study, we sought to determine the immunological aspects during H. pylori infection and gastric cancer development. We found that B cells from H. pylori-infected patients presented altered composition and function compared to uninfected patients...
2015: PloS One
David E Gerber, Paul K Paik, Afshin Dowlati
Lung cancer encompasses a diverse spectrum of histologic subtypes. Until recently, the majority of therapeutic advances were limited to the minority of patients with adenocarcinoma. With the advent of comprehensive genomic profiling of squamous and small cell lung cancers, new therapeutic targets have emerged. For squamous tumors, the most promising of these include fibroblast growth factor receptor (FGFR), the phosphatidylinositol 3-kinase (PI3K) pathway, discoidin domain receptor 2 (DDR2), and G1/S checkpoint regulators...
2015: American Society of Clinical Oncology Educational Book
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin, Marc Ladanyi
UNLABELLED: Mutations in the MET exon 14 RNA splice acceptor and donor sites, which lead to exon skipping, deletion of the juxtamembrane domain containing the CBL E3-ubiquitin ligase-binding site, and decreased turnover of the resultant aberrant MET protein, were previously reported to be oncogenic in preclinical models. We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping, highlighting a new therapeutic strategy for the 4% of lung adenocarcinoma patients whose tumors harbor this previously underappreciated genetic alteration...
August 2015: Cancer Discovery
Paul K Paik, Ronglai Shen, Helen Won, Natasha Rekhtman, Lu Wang, Camelia S Sima, Arshi Arora, Venkatraman Seshan, Marc Ladanyi, Michael F Berger, Mark G Kris
UNLABELLED: Large-scale genomic characterization of squamous cell lung cancers (SQCLC) has revealed several putative oncogenic drivers. There are, however, little data to suggest that these alterations have clinical relevance. We performed comprehensive genomic profiling (including next-generation sequencing) of 79 stage IV SQCLCs and analyzed differences in the clinical characteristics of two major SQCLC subtypes: FGFR1 amplified and PI3K aberrant. Patients with PI3K-aberrant tumors had aggressive disease marked by worse survival (median overall survival, 8...
June 2015: Cancer Discovery
Anya M Litvak, Paul K Paik, Kaitlin M Woo, Camelia S Sima, Matthew D Hellmann, Maria E Arcila, Marc Ladanyi, Charles M Rudin, Mark G Kris, Gregory J Riely
INTRODUCTION: Mutant BRAF is a driver oncogene found in 2% of lung adenocarcinomas and represents a target for therapy. We examined the clinical characteristics and course of patients with lung adenocarcinomas harboring BRAF mutations. METHODS: We identified patients with lung adenocarcinomas harboring BRAF mutations between 2009 and 2013 detected using a mass spectrometry-based polymerase chain reaction genotyping assay of hot-spot mutations involving codons corresponding to amino acids V600, D594, and G469 of BRAF...
November 2014: Journal of Thoracic Oncology
Christine M Lovly, Nerina T McDonald, Heidi Chen, Sandra Ortiz-Cuaran, Lukas C Heukamp, Yingjun Yan, Alexandra Florin, Luka Ozretić, Diana Lim, Lu Wang, Zhao Chen, Xi Chen, Pengcheng Lu, Paul K Paik, Ronglai Shen, Hailing Jin, Reinhard Buettner, Sascha Ansén, Sven Perner, Michael Brockmann, Marc Bos, Jürgen Wolf, Masyar Gardizi, Gavin M Wright, Benjamin Solomon, Prudence A Russell, Toni-Maree Rogers, Yoshiyuki Suehara, Monica Red-Brewer, Rudy Tieu, Elisa de Stanchina, Qingguo Wang, Zhongming Zhao, David H Johnson, Leora Horn, Kwok-Kin Wong, Roman K Thomas, Marc Ladanyi, William Pao
Crizotinib, a selective tyrosine kinase inhibitor (TKI), shows marked activity in patients whose lung cancers harbor fusions in the gene encoding anaplastic lymphoma receptor tyrosine kinase (ALK), but its efficacy is limited by variable primary responses and acquired resistance. In work arising from the clinical observation of a patient with ALK fusion-positive lung cancer who had an exceptional response to an insulin-like growth factor 1 receptor (IGF-1R)-specific antibody, we define a therapeutic synergism between ALK and IGF-1R inhibitors...
September 2014: Nature Medicine
Aditya Sood, Paul J Therattil, Angie M Paik, Mary F Simpson, Edward S Lee
INTRODUCTION: Clinical trials seeking to establish long-term efficacy of injectable collagenase clostridium histolyticum for treatment of Dupuytren disease are ongoing. In this quality improvement study, the efficacy, recurrence rate, and complications of collagenase injection for Dupuytren disease are reviewed in a population of Veteran patients. MATERIALS AND METHODS: A retrospective chart review was performed for patients who underwent treatment with injectable collagenase for Dupuytren disease from 2010 to 2013 at our regional Department of Veterans Affairs medical center...
2014: Eplasty
Paul Y Paik, Michelle Capdeville, Andra E Duncan
No abstract text is available yet for this article.
January 2014: Anesthesia and Analgesia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"